CircNova, Inc. is a biotechnology company that leverages our unique AI NovaEngine™ to generate, analyze and identify circular RNA for therapeutic development.
Our experts focus on non-coding RNA with many mechanisms of action against undruggable disease targets for major unmet clinical needs.
CircNova is developing a robust IP portfolio for development of circRNA therapeutics.
We are driven by our passion to innovate, discover and lead the development of life-changing RNA based therapies.
We offer partners and patients new solutions to previously undruggable targets that lead to better quality of life.
Generative Artificial Intelligence has arrived to deliver novel applications in drug discovery, gene therapy, and biotechnology.
AI-guided RNA-folding and active structure prediction coupled with high-throughput RNA synthesis enables revolutionary efficiencies in effective development of therapeutic candidates.
Our AI NovaEngine™ is the first in the world to predict circular RNA structures using deep-learning, allowing unprecedented capability in therapeutic design for "undruggable" diseases, such as Triple-negative Breast Cancer.
Former CEO, Great Lakes Biologics
Former CEO, Neochromosome
Former CSO, Apex Bioscience
Great Lakes Biologics
Former CTO, Genomenon
Former CTO, CarCode
Associate Professor, the University of Michigan
Francis S. Collins Collegiate Professor of Chemistry, Biophysics, and Biological Chemistry, University of Michigan
CEO, Reveal Pharmaceuticals
SVP, Life Sciences, Banc of California